US-based antibody research company KaloBios Pharmaceuticals has raised $70m in its IPO.
KaloBios Pharmaceuticals, a developer of monoclonal antibody therapeutics for cancers and respiratory diseases, has raised around $70m in its IPO, according to a recent filing.
The company priced 8.8 million shares at $8 per share, compared to recently-revised plans to offer 8.25 million shares at between $8 and $9 per share. Its initial market cap is about $191m. Leerink Swann served as the lead underwriter.
Initially the company had planned to sell 3.85 million shares priced at around $12 to…
